Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.